menu

Innovative therapeutic approaches in hypertrophic cardiomyopathy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Innovative therapeutic approaches in hypertrophic cardiomyopathy

3 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Hypertrophic cardiomyopathy (HCM) is more than just a thickened heart. This series of three presentations provides insights into the etiology and pathogenesis of this complex disease, how to make the diagnosis, and the therapeutic options.

    Dr. Antonis Pantazis starts his presentation off with a scientific definition of HCM and explains what distinguishes it from other conditions that feature a “thick heart.” Dr. Michelle Michels highlights the importance of a thorough work-up in patients with LV hypertrophy to make the correct diagnosis. Prof. Iacopo Olivotto discusses the study results of mavacamten, a drug specifically designed for treating HCM.

    This course consists of the following:

    • Unhiding hypertrophic cardiomyopathy, a call for action - Antonis Pantazis, MD - London, UK
    • Hypertrophic cardiomyopathy: making the diagnosis - Michelle Michels, MD, PhD - Rotterdam, the Netherlands
    • Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape? - Prof. Iacopo Olivotto, MD - Florence, Italy
  • How to obtain your CME certificate

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate (if your score >70%)
  • Learning Objectives

    After watching these three videos, the learner should be able to:

    • Describe how HCM can be distinguished from other conditions that feature a thickened heart
    • List the steps that should be included in the diagnostic work-up of patients with signs of LV hypertrophy
    • Recall the diagnostic tests for diagnosing HCM
    • Describe the mechanism of action of mavacamten
    • Summarize the main findings of phase 3 studies with mavacamten in symptomatic obstructive HCM patients
  • Expert faculty

    • Antonis Pantazis, MD - London, UK
    • Michelle Michels, MD, PhD - Rotterdam, the Netherlands
    • Prof. Iacopo Olivotto, MD - Florence, Italy
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with hypertrophic cardiomyopathy.

  • CME accreditation

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.

  • Questions

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Hypertrophic cardiomyopathy (HCM) is more than just a thickened heart. This series of three presentations provides insights into the etiology and pathogenesis of this complex disease, how to make the diagnosis, and the therapeutic options.

    Dr. Antonis Pantazis starts his presentation off with a scientific definition of HCM and explains what distinguishes it from other conditions that feature a “thick heart.” Dr. Michelle Michels highlights the importance of a thorough work-up in patients with LV hypertrophy to make the correct diagnosis. Prof. Iacopo Olivotto discusses the study results of mavacamten, a drug specifically designed for treating HCM.

    This course consists of the following:

    • Unhiding hypertrophic cardiomyopathy, a call for action - Antonis Pantazis, MD - London, UK
    • Hypertrophic cardiomyopathy: making the diagnosis - Michelle Michels, MD, PhD - Rotterdam, the Netherlands
    • Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape? - Prof. Iacopo Olivotto, MD - Florence, Italy
  • How to obtain your CME certificate

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate (if your score >70%)
  • Learning Objectives

    After watching these three videos, the learner should be able to:

    • Describe how HCM can be distinguished from other conditions that feature a thickened heart
    • List the steps that should be included in the diagnostic work-up of patients with signs of LV hypertrophy
    • Recall the diagnostic tests for diagnosing HCM
    • Describe the mechanism of action of mavacamten
    • Summarize the main findings of phase 3 studies with mavacamten in symptomatic obstructive HCM patients
  • Expert faculty

    • Antonis Pantazis, MD - London, UK
    • Michelle Michels, MD, PhD - Rotterdam, the Netherlands
    • Prof. Iacopo Olivotto, MD - Florence, Italy
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with hypertrophic cardiomyopathy.

  • CME accreditation

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.

  • Questions

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule8 Feb 2023